Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium butyricum MIYAIRI 588 modulation of gut microbiota and immune status in cancer patients
ChiCTR2100043876Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Feb 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of clostridium butyricum in cancer (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Gut microbiome. Started Feb 2021; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2100043876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043876.